| Field | Specification |
|---|---|
| Target | |
| Alternative names | Cdc42 effector protein 1; cdc42ep1.L |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Conjugate | |
| Purification | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets cdc42 effector protein 1 (gene cdc42ep1.L) in african clawed frog samples.
In Xenopus laevis, cdc42ep1.L is one of the two homeologous copies of the gene encoding CDC42 effector protein 1. Its function in frog has not been fully characterized; in mammals, the related protein binds active CDC42 and is linked to actin cytoskeleton organization.
| Target | Cdc42 effector protein 1 (gene cdc42ep1.L; UniProt A0A1L8GP22, Xenopus laevis) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | African clawed frog |
| Form | Liquid |
| Formulation | 20 mM PBS; 50% glycerol; 0.02% NaN3 |
| Storage | Store at −20 °C for up to 12 months or 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Reactivity Notes
The supplier lists reactivity with african clawed frog. UniProt places cdc42 effector protein 1 in the endomembrane system.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
